While each product featured is independently selected by our editors, we may include paid promotion. If you buy something through our links, we may earn commission. Read more about our Product Review ...
The Braftovi-Erbitux combination will become the preferred second-line treatment option in treatment of adults with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, according to one ...
Wu Xiaohui of Wanhuida Intellectual Property examines how a recent CNIPA decision reinforces the need for a holistic inventive step assessment when evaluating pharmaceutical combination formulations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback